Lupin’s Biosimilars Strategy Anchored By Japan
This article was originally published in PharmAsia News
Lupin may have been slow off the block in the biosimilars space in emerging markets compared with some of its Indian peers, but the Mumbai-based firm is hoping that a new strategy centered around its "anchor market" Japan may more than compensate, as well as propelling its entry into the U.S. and Europe.
You may also be interested in...
Scrip traces some of the prominent changes in the corner office at front-line, family-owned Indian firms Cipla and Dr Reddy’s in the decade gone by.
Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.